Table 4.
Top 30 antineoplastics implicated in haematological adverse reactions.
| Ranking | Drug | Cases | ROR (95% CI) | PRR (χ²) | EBGM (EBGM05) | IC (IC025) |
|---|---|---|---|---|---|---|
| 1 | Lenalidomide* | 21246 | 1.51 (1.49-1.53) | 1.48 (3331) | 1.47 (1.44) | 0.55 (0.53) |
| 2 | Methotrexate* | 14837 | 2.98 (2.93-3.04) | 2.77 (17114.68) | 2.73 (2.69) | 1.45 (1.43) |
| 3 | Rituximab | 14439 | 3.69 (3.63-3.76) | 3.34 (24210.50) | 3.30 (3.24) | 1.72 (1.70) |
| 4 | Carboplatin* | 11119 | 7.46 (7.31-7.62) | 5.95 (47014.76) | 5.88 (5.76) | 2.56 (2.52) |
| 5 | Palbociclib* | 8936 | 3.08 (3.01-3.15) | 2.85 (11026.35) | 2.83 (2.76) | 1.50 (1.47) |
| 6 | Doxorubicin* | 8528 | 8.13 (7.93-8.33) | 6.34 (39543.31) | 6.29 (6.13) | 2.65 (2.62) |
| 7 | Bevacizumab | 8390 | 3.17 (3.09-3.24) | 2.92 (10882.87) | 2.90 (2.83) | 1.53 (1.50) |
| 8 | Ruxolitinib* | 8108 | 3.46 (3.38-3.54) | 3.15 (12270.23) | 3.13 (3.06) | 1.65 (1.61) |
| 9 | Gemcitabine* | 7502 | 9.02 (8.79-9.27) | 6.85 (38681.14) | 6.80 (6.62) | 2.76 (2.73) |
| 10 | Venetoclax* | 7351 | 4.94 (4.82-5.06) | 4.27 (19014.82) | 4.24 (4.14) | 2.08 (2.05) |
| 11 | Cyclophosphamide* | 7342 | 7.39 (7.20-7.58) | 5.90 (30823.86) | 5.85 (5.70) | 2.55 (2.51) |
| 12 | Pembrolizumab | 5562 | 2.70 (2.62-2.77) | 2.53 (5307.30) | 2.52 (2.45) | 1.33 (1.29) |
| 13 | Paclitaxel* | 5554 | 4.19 (4.07-4.31) | 3.72 (11414.05) | 3.70 (3.59) | 1.89 (1.84) |
| 14 | Oxaliplatin* | 5481 | 4.68 (4.54-4.81) | 4.08 (13185.56) | 4.06 (3.94) | 2.02 (1.98) |
| 15 | Ibrutinib* | 5370 | 2.06 (2.01-2.12) | 1.98 (2694.13) | 1.97 (1.92) | 0.98 (0.94) |
| 16 | Imatinib* | 5149 | 2.37 (2.30-2.44) | 2.25 (3678.95) | 2.24 (2.17) | 1.16 (1.12) |
| 17 | Cisplatin* | 5101 | 8.77 (8.49-9.06) | 6.71 (25632.09) | 6.67 (6.46) | 2.74 (2.69) |
| 18 | Trastuzumab | 4982 | 3.96 (3.84-4.08) | 3.54 (9412.33) | 3.53 (3.42) | 1.82 (1.77) |
| 19 | Capecitabine* | 4809 | 2.18 (2.12-2.25) | 2.09 (2810.86) | 2.08 (2.02) | 1.06 (1.01) |
| 20 | Cytarabine* | 4754 | 14.82 (14.29-15.36) | 9.58 (37808.39) | 9.53 (9.19) | 3.25 (3.20) |
| 21 | Docetaxel* | 4727 | 2.41 (2.34-2.48) | 2.28 (3527.78) | 2.28 (2.21) | 1.19 (1.14) |
| 22 | Peginterferon Alfa 2A* | 4576 | 4.12 (3.99-4.25) | 3.67 (9195.13) | 3.65 (3.54) | 1.87 (1.82) |
| 23 | Azacitidine* | 4495 | 8.60 (8.31-8.90) | 6.61 (22158.43) | 6.58 (6.36) | 2.72 (2.67) |
| 24 | Fluorouracil* | 4427 | 6.55 (6.33-6.77) | 5.37 (16289.21) | 5.34 (5.17) | 2.42 (2.37) |
| 25 | Pomalidomide* | 4358 | 1.30 (1.26-1.34) | 1.28 (284.39) | 1.28 (1.24) | 0.36 (0.31) |
| 26 | Nivolumab | 4232 | 1.65 (1.60-1.70) | 1.61 (1007.46) | 1.60 (1.56) | 0.68 (0.64) |
| 27 | Bortezomib* | 3848 | 3.12 (3.02-3.23) | 2.88 (4892.40) | 2.87 (2.78) | 1.52 (1.47) |
| 28 | Letrozole | 3835 | 5.38 (5.20-5.57) | 4.58 (11138.16) | 4.57 (4.41) | 2.19 (2.14) |
| 29 | Etoposide* | 3480 | 9.19 (8.83-9.55) | 6.94 (18326.34) | 6.91 (6.64) | 2.79 (2.73) |
| 30 | Sunitinib* | 3346 | 2.39 (2.31-2.48) | 2.27 (2453.14) | 2.26 (2.18) | 1.18 (1.12) |
ADE, adverse drug event; CI, confidence interval; ROR, Reporting Odds Ratio; PRR, Proportional Reporting Ratio; BCPNN, Bayesian Confidence Propagation Neural Network; MGPS, Multi - item Gamma Poisson Shrinker; *warnings related to haematological toxicity risk.